IFITM3 Polyclonal Antibody (D-AB-10162L)

-
-
-
- +3
For research use only.
Verified Samples |
Verified Samples in WB: Human Hela, Human 293 T, Mouse Liver, Mouse Heart, Rat Liver Verified Samples in IHC: Rat kidney, Mouse lung, Human lung Verified Samples in IF: Human Hela |
Dilution | WB 1:1000-1:2000, IHC 1:50-1:200, IF 1:100-1:400 |
Isotype | IgG |
Host | Rabbit |
Reactivity | Human, Mouse, Rat |
Applications | WB, IHC, IF |
Clonality | Polyclonal |
Immunogen | Recombinant Rat IFITM3 protein expressed by E.coli |
Abbre | IFITM3 |
Synonyms | 1 8U, Fragilis, IFITM3, IFM3, Interferon Induced Transmembrane Protein 3, Interferon Inducible Protein 15, Interferon Inducible Protein Homolog, Interferon induced transmembrane protein 3 (1 8U), Interferon inducible, Interferon inducible protein 1 8U, Interferon-i |
Swissprot | |
Calculated MW | 15 kDa |
Observed MW |
15 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
Concentration | 1 mg/mL |
Buffer | PBS with 0.05% proclin 300, 1% protective protein and 50% glycerol,pH7.4 |
Purification Method | Antigen Affinity Purification |
Research Areas | Cancer, Developmental Biology, Stem Cells |
Conjugation | Unconjugated |
Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
Shipping | The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended. |
background | IFITM3,also named as interferon-inducible protein 1-8U,belongs to the CD225 family. It is IFN-induced antiviral protein that mediates cellular innate immunity to at least three major human pathogens,namely influenza A H1N1 virus,West Nile virus (WNV),and dengue virus,by inhibiting the early steps of replication. IFITM3 is identified as interferon-induced cellular proteins that restrict infections by retroviruses and filoviruses and of influenza virus and flaviviruses,respectively. IFITM3,the most potent antiviral IFITM,was found to inhibit an uncharacterized early infectious event after VSV endocytosis,but before primary transcription of its viral genome. IFITM proteins are viral restriction factors that can inhibit infection mediated by the influenza A virus (IAV) hemagglutinin (HA) protein. They differentially restrict the entry of a broad range of enveloped viruses,and modulate cellular tropism independently of viral receptor expression. This antibody recognizes both IFITM2 and IFITM3. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.:{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.:{{item.cat}}
{{index}} {{goods_show_value}}
-
IF:{{item.impact}}
Journal:{{item.journal}} ({{item.year}})
DOI:{{item.doi}}Reactivity:{{item.species}}
Sample Type:{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}